Abstract
Summary
The global Medical Nicotine Transdermal Skin Patch market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Medical Nicotine Transdermal Skin Patch is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Medical Nicotine Transdermal Skin Patch is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Medical Nicotine Transdermal Skin Patch is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Medical Nicotine Transdermal Skin Patch players cover Habitrol, Nicotrol, Nicoderm, Aroamas Cot, Hisamitsu Pharmaceutica, Novartis, Johnson & Johnson, Teikoku Pharma and Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Medical Nicotine Transdermal Skin Patch Industry Forecast” looks at past sales and reviews total world Medical Nicotine Transdermal Skin Patch sales in 2022, providing a comprehensive analysis by region and market sector of projected Medical Nicotine Transdermal Skin Patch sales for 2023 through 2029. With Medical Nicotine Transdermal Skin Patch sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medical Nicotine Transdermal Skin Patch industry.
This Insight Report provides a comprehensive analysis of the global Medical Nicotine Transdermal Skin Patch landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Medical Nicotine Transdermal Skin Patch portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Medical Nicotine Transdermal Skin Patch market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medical Nicotine Transdermal Skin Patch and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medical Nicotine Transdermal Skin Patch.
This report presents a comprehensive overview, market shares, and growth opportunities of Medical Nicotine Transdermal Skin Patch market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
21 mg
14 mg
7 mg
Segmentation by application
Smoking Cessation Centres
Hospitals
Home
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Habitrol
Nicotrol
Nicoderm
Aroamas Cot
Hisamitsu Pharmaceutica
Novartis
Johnson & Johnson
Teikoku Pharma
Mylan
Actavis
Mundipharma
Henan Lingrui pharmaceutical
Changzhou Siyao
Rfl Pharmaceutical
Luye Pharma Group Ltd.
Purdue Pharma L.P
Teva Pharmaceutical Industries
Key Questions Addressed in this Report
What is the 10-year outlook for the global Medical Nicotine Transdermal Skin Patch market?
What factors are driving Medical Nicotine Transdermal Skin Patch market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Medical Nicotine Transdermal Skin Patch market opportunities vary by end market size?
How does Medical Nicotine Transdermal Skin Patch break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
United States market for Medical Nicotine Transdermal Skin Patch is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Medical Nicotine Transdermal Skin Patch is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Medical Nicotine Transdermal Skin Patch is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Medical Nicotine Transdermal Skin Patch players cover Habitrol, Nicotrol, Nicoderm, Aroamas Cot, Hisamitsu Pharmaceutica, Novartis, Johnson & Johnson, Teikoku Pharma and Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Medical Nicotine Transdermal Skin Patch Industry Forecast” looks at past sales and reviews total world Medical Nicotine Transdermal Skin Patch sales in 2022, providing a comprehensive analysis by region and market sector of projected Medical Nicotine Transdermal Skin Patch sales for 2023 through 2029. With Medical Nicotine Transdermal Skin Patch sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medical Nicotine Transdermal Skin Patch industry.
This Insight Report provides a comprehensive analysis of the global Medical Nicotine Transdermal Skin Patch landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Medical Nicotine Transdermal Skin Patch portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Medical Nicotine Transdermal Skin Patch market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medical Nicotine Transdermal Skin Patch and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medical Nicotine Transdermal Skin Patch.
This report presents a comprehensive overview, market shares, and growth opportunities of Medical Nicotine Transdermal Skin Patch market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
21 mg
14 mg
7 mg
Segmentation by application
Smoking Cessation Centres
Hospitals
Home
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Habitrol
Nicotrol
Nicoderm
Aroamas Cot
Hisamitsu Pharmaceutica
Novartis
Johnson & Johnson
Teikoku Pharma
Mylan
Actavis
Mundipharma
Henan Lingrui pharmaceutical
Changzhou Siyao
Rfl Pharmaceutical
Luye Pharma Group Ltd.
Purdue Pharma L.P
Teva Pharmaceutical Industries
Key Questions Addressed in this Report
What is the 10-year outlook for the global Medical Nicotine Transdermal Skin Patch market?
What factors are driving Medical Nicotine Transdermal Skin Patch market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Medical Nicotine Transdermal Skin Patch market opportunities vary by end market size?
How does Medical Nicotine Transdermal Skin Patch break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Medical Nicotine Transdermal Skin Patch Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Medical Nicotine Transdermal Skin Patch by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Medical Nicotine Transdermal Skin Patch by Country/Region, 2018, 2022 & 2029
2.2 Medical Nicotine Transdermal Skin Patch Segment by Type
2.2.1 21 mg
2.2.2 14 mg
2.2.3 7 mg
2.3 Medical Nicotine Transdermal Skin Patch Sales by Type
2.3.1 Global Medical Nicotine Transdermal Skin Patch Sales Market Share by Type (2018-2023)
2.3.2 Global Medical Nicotine Transdermal Skin Patch Revenue and Market Share by Type (2018-2023)
2.3.3 Global Medical Nicotine Transdermal Skin Patch Sale Price by Type (2018-2023)
2.4 Medical Nicotine Transdermal Skin Patch Segment by Application
2.4.1 Smoking Cessation Centres
2.4.2 Hospitals
2.4.3 Home
2.4.4 Others
2.5 Medical Nicotine Transdermal Skin Patch Sales by Application
2.5.1 Global Medical Nicotine Transdermal Skin Patch Sale Market Share by Application (2018-2023)
2.5.2 Global Medical Nicotine Transdermal Skin Patch Revenue and Market Share by Application (2018-2023)
2.5.3 Global Medical Nicotine Transdermal Skin Patch Sale Price by Application (2018-2023)
3 Global Medical Nicotine Transdermal Skin Patch by Company
3.1 Global Medical Nicotine Transdermal Skin Patch Breakdown Data by Company
3.1.1 Global Medical Nicotine Transdermal Skin Patch Annual Sales by Company (2018-2023)
3.1.2 Global Medical Nicotine Transdermal Skin Patch Sales Market Share by Company (2018-2023)
3.2 Global Medical Nicotine Transdermal Skin Patch Annual Revenue by Company (2018-2023)
3.2.1 Global Medical Nicotine Transdermal Skin Patch Revenue by Company (2018-2023)
3.2.2 Global Medical Nicotine Transdermal Skin Patch Revenue Market Share by Company (2018-2023)
3.3 Global Medical Nicotine Transdermal Skin Patch Sale Price by Company
3.4 Key Manufacturers Medical Nicotine Transdermal Skin Patch Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Medical Nicotine Transdermal Skin Patch Product Location Distribution
3.4.2 Players Medical Nicotine Transdermal Skin Patch Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Medical Nicotine Transdermal Skin Patch by Geographic Region
4.1 World Historic Medical Nicotine Transdermal Skin Patch Market Size by Geographic Region (2018-2023)
4.1.1 Global Medical Nicotine Transdermal Skin Patch Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Medical Nicotine Transdermal Skin Patch Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Medical Nicotine Transdermal Skin Patch Market Size by Country/Region (2018-2023)
4.2.1 Global Medical Nicotine Transdermal Skin Patch Annual Sales by Country/Region (2018-2023)
4.2.2 Global Medical Nicotine Transdermal Skin Patch Annual Revenue by Country/Region (2018-2023)
4.3 Americas Medical Nicotine Transdermal Skin Patch Sales Growth
4.4 APAC Medical Nicotine Transdermal Skin Patch Sales Growth
4.5 Europe Medical Nicotine Transdermal Skin Patch Sales Growth
4.6 Middle East & Africa Medical Nicotine Transdermal Skin Patch Sales Growth
5 Americas
5.1 Americas Medical Nicotine Transdermal Skin Patch Sales by Country
5.1.1 Americas Medical Nicotine Transdermal Skin Patch Sales by Country (2018-2023)
5.1.2 Americas Medical Nicotine Transdermal Skin Patch Revenue by Country (2018-2023)
5.2 Americas Medical Nicotine Transdermal Skin Patch Sales by Type
5.3 Americas Medical Nicotine Transdermal Skin Patch Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Medical Nicotine Transdermal Skin Patch Sales by Region
6.1.1 APAC Medical Nicotine Transdermal Skin Patch Sales by Region (2018-2023)
6.1.2 APAC Medical Nicotine Transdermal Skin Patch Revenue by Region (2018-2023)
6.2 APAC Medical Nicotine Transdermal Skin Patch Sales by Type
6.3 APAC Medical Nicotine Transdermal Skin Patch Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Medical Nicotine Transdermal Skin Patch by Country
7.1.1 Europe Medical Nicotine Transdermal Skin Patch Sales by Country (2018-2023)
7.1.2 Europe Medical Nicotine Transdermal Skin Patch Revenue by Country (2018-2023)
7.2 Europe Medical Nicotine Transdermal Skin Patch Sales by Type
7.3 Europe Medical Nicotine Transdermal Skin Patch Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Medical Nicotine Transdermal Skin Patch by Country
8.1.1 Middle East & Africa Medical Nicotine Transdermal Skin Patch Sales by Country (2018-2023)
8.1.2 Middle East & Africa Medical Nicotine Transdermal Skin Patch Revenue by Country (2018-2023)
8.2 Middle East & Africa Medical Nicotine Transdermal Skin Patch Sales by Type
8.3 Middle East & Africa Medical Nicotine Transdermal Skin Patch Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Medical Nicotine Transdermal Skin Patch
10.3 Manufacturing Process Analysis of Medical Nicotine Transdermal Skin Patch
10.4 Industry Chain Structure of Medical Nicotine Transdermal Skin Patch
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Medical Nicotine Transdermal Skin Patch Distributors
11.3 Medical Nicotine Transdermal Skin Patch Customer
12 World Forecast Review for Medical Nicotine Transdermal Skin Patch by Geographic Region
12.1 Global Medical Nicotine Transdermal Skin Patch Market Size Forecast by Region
12.1.1 Global Medical Nicotine Transdermal Skin Patch Forecast by Region (2024-2029)
12.1.2 Global Medical Nicotine Transdermal Skin Patch Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Medical Nicotine Transdermal Skin Patch Forecast by Type
12.7 Global Medical Nicotine Transdermal Skin Patch Forecast by Application
13 Key Players Analysis
13.1 Habitrol
13.1.1 Habitrol Company Information
13.1.2 Habitrol Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.1.3 Habitrol Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Habitrol Main Business Overview
13.1.5 Habitrol Latest Developments
13.2 Nicotrol
13.2.1 Nicotrol Company Information
13.2.2 Nicotrol Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.2.3 Nicotrol Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Nicotrol Main Business Overview
13.2.5 Nicotrol Latest Developments
13.3 Nicoderm
13.3.1 Nicoderm Company Information
13.3.2 Nicoderm Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.3.3 Nicoderm Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Nicoderm Main Business Overview
13.3.5 Nicoderm Latest Developments
13.4 Aroamas Cot
13.4.1 Aroamas Cot Company Information
13.4.2 Aroamas Cot Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.4.3 Aroamas Cot Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Aroamas Cot Main Business Overview
13.4.5 Aroamas Cot Latest Developments
13.5 Hisamitsu Pharmaceutica
13.5.1 Hisamitsu Pharmaceutica Company Information
13.5.2 Hisamitsu Pharmaceutica Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.5.3 Hisamitsu Pharmaceutica Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Hisamitsu Pharmaceutica Main Business Overview
13.5.5 Hisamitsu Pharmaceutica Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.6.3 Novartis Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.7.3 Johnson & Johnson Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Teikoku Pharma
13.8.1 Teikoku Pharma Company Information
13.8.2 Teikoku Pharma Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.8.3 Teikoku Pharma Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Teikoku Pharma Main Business Overview
13.8.5 Teikoku Pharma Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.9.3 Mylan Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Actavis
13.10.1 Actavis Company Information
13.10.2 Actavis Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.10.3 Actavis Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Actavis Main Business Overview
13.10.5 Actavis Latest Developments
13.11 Mundipharma
13.11.1 Mundipharma Company Information
13.11.2 Mundipharma Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.11.3 Mundipharma Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Mundipharma Main Business Overview
13.11.5 Mundipharma Latest Developments
13.12 Henan Lingrui pharmaceutical
13.12.1 Henan Lingrui pharmaceutical Company Information
13.12.2 Henan Lingrui pharmaceutical Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.12.3 Henan Lingrui pharmaceutical Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Henan Lingrui pharmaceutical Main Business Overview
13.12.5 Henan Lingrui pharmaceutical Latest Developments
13.13 Changzhou Siyao
13.13.1 Changzhou Siyao Company Information
13.13.2 Changzhou Siyao Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.13.3 Changzhou Siyao Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Changzhou Siyao Main Business Overview
13.13.5 Changzhou Siyao Latest Developments
13.14 Rfl Pharmaceutical
13.14.1 Rfl Pharmaceutical Company Information
13.14.2 Rfl Pharmaceutical Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.14.3 Rfl Pharmaceutical Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Rfl Pharmaceutical Main Business Overview
13.14.5 Rfl Pharmaceutical Latest Developments
13.15 Luye Pharma Group Ltd.
13.15.1 Luye Pharma Group Ltd. Company Information
13.15.2 Luye Pharma Group Ltd. Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.15.3 Luye Pharma Group Ltd. Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Luye Pharma Group Ltd. Main Business Overview
13.15.5 Luye Pharma Group Ltd. Latest Developments
13.16 Purdue Pharma L.P
13.16.1 Purdue Pharma L.P Company Information
13.16.2 Purdue Pharma L.P Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.16.3 Purdue Pharma L.P Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Purdue Pharma L.P Main Business Overview
13.16.5 Purdue Pharma L.P Latest Developments
13.17 Teva Pharmaceutical Industries
13.17.1 Teva Pharmaceutical Industries Company Information
13.17.2 Teva Pharmaceutical Industries Medical Nicotine Transdermal Skin Patch Product Portfolios and Specifications
13.17.3 Teva Pharmaceutical Industries Medical Nicotine Transdermal Skin Patch Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Teva Pharmaceutical Industries Main Business Overview
13.17.5 Teva Pharmaceutical Industries Latest Developments
14 Research Findings and Conclusion